You are here: Industry Insights > acute lymphoblastic leukemia

News List

FDA Approves Treatment Regimen for Most Prevalent Childhood Cancer americanpharmaceuticalreview
July 05, 2021
The FDA approved Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the ...
5 months after launch, Allogene guns for $100M IPO fiercebiotech
September 18, 2018
Allogene licensed its allogeneic CAR-T pipeline from Cellectis by way of Pfizer.
Shire completes sale of oncology franchise to Servier pharmatimes
September 14, 2018
Shire has completed the sale of its oncology franchise to Servier in a deal valued at $2.4 billion.
CAR-T therapies leap towards EU approval pharmatimes
July 04, 2018
The stage has been set for approval of the first chimeric antigen T-cell therapies (CAR-T) in Europe, after Novartis’ Kymriah and Gilead’s Yescarta both won backing from the Committee for Medicinal Products for Human Use (CHMP).
Novartis CEO opens door to cancer patient demanding ‘fair’ CAR-T pricing fiercepharma
August 22, 2017
Novartis CEO Joe Jimenez granted a cancer patient's request for a meeting at the company to discuss CAR-T pricing as its med tisagenlecleucel (CTL019) awaits an FDA decision date in October.
BESPONSA® approved in the EU for adult patients with relapsed or refractory B-cell precursor acute l worldpharmanews
July 13, 2017
Pfizer Inc. (NYSE:PFE) announced that the European Commission has approved BESPONSA® (inotuzumab ozogamicin) as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).
EC approves Pfizer’s acute lymphoblastic leukemia treatment Besponsa pharmaceutical-technology
July 05, 2017
The European Commission (EC) has approved Pfizer’s Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL) in the European Union (EU).